Three things to know:
1. Varian Medical will acquire Oncozene, Embozene and Embozene Tandem, Boston Scientific’s products that treat arteriovenous malformations in the brain and spine.
2. The three products accumulated $21.2 million in sales in 2018.
3. The deal will be completed after Boston Scientific finalizes the acquisition of BTG, expected in August.
More articles on devices:
8 leadership changes in spine, orthopedic device companies in June
Fusion Robotics to advance spinal robotic devices
Alexion drug receives FDA approval for rare autoimmune disease of spinal cord
